<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BD6B9D64-0FDD-4F7D-BC9A-26B516577FAF"><gtr:id>BD6B9D64-0FDD-4F7D-BC9A-26B516577FAF</gtr:id><gtr:firstName>Lynn</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700128"><gtr:id>BDAB48C0-E876-40D4-A858-0679F6896174</gtr:id><gtr:title>STAT3 is a central mediator of the anti-inflammatory response;identification of its mechanism of action</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700128</gtr:grantReference><gtr:abstractText>Inflammation is an important mechanism by which the body mounts an immune response to infection. However if inflammation is excessive it can lead to serious diseases such as rheumatoid arthritis, Crohn?s disease and atherosclerosis. Many auto-immune diseases and inflammatory conditions are caused by an over production of pro-inflammatory ?immunological hormones? called cytokines. These are proteins released from cells of the immune system to orchestrate the immune response. In healthy individuals during the course of an immune response there is an initial burst of pro-inflammatory cytokines production which primes the immune cells to kill invading pathogens such as bacteria and viruses. The production of these pro-inflammatory cytokines must be tightly controlled and their production is subsequently ?turned off? by a secondary release of different cytokines called anti-inflammatory cytokines once the invading pathogens have been cleared. One of the most potent anti-inflammatory cytokines is called interleukin-10. The aim of this proposal is to determine how one of the key molecules activated by IL-10, called STAT3, regulates IL-10?s immunosuppressive effects. Specifically we aim to investigate which genes STAT3 regulates and the mechanism by which STAT induces these anti-inflammatory genes in human immune cells. This work will be carried out at the Kennedy Institute of Rheumatology that is part of Imperial College, London. The Kennedy Institute is one of the world?s foremost centres of inflammation research. The study will use primary human cells so that the work is as relevant as possible to human physiology. 

A greater understanding off inflammation and how our body?s own natural immunosuppressive molecules work will lead to the generation of new specific therapies that could better control the excessive inflammation behind these key diseases. Results generated from this study will be submitted to peer reviewed, widely read scientific journals. Data will also be available for public scrutiny at both national and international meetings of organisations such as the international cytokine society and the British Society of Immunology. In addition, publicly available, annual reports from the Kennedy Institute will include details of the research in lay terms</gtr:abstractText><gtr:technicalSummary>To avoid an exaggerated inflammatory response, the immune system must be tightly controlled and has evolved a complex network to control and orchestrate the resolution of the acute inflammatory response. Two important mediators of this anti-inflammatory responses; IL-10 and nicotine (cholinergic pathway), both mediate their anti-inflammatory effects via the activation of the transcription factor STAT3. However, the mechanism by which these diverse stimuli utilize STAT3 to drive the anti-inflammatory response remains largely unresolved.
We have shown that the cellular context of STAT3 appears to dictate whether it drives an anti-inflammatory verses an oncogenic response, so a clearer understanding of how this molecule can generate such polarized response it vital. To date however, no such studies have been undertaken to dissect these important aspects of STAT3 function. The aim of this proposal is the fully characterize at the genomic and proteomic level how the transcription factor STAT3 suppresses cytokine gene expression in myeloid cells. Using a constitutive form of STAT3 we have demonstrated that activated STAT3 can mimic the cytokine suppressive properties of interleukin-10 in myeloid but conversely not in non-myeloid cells. By using Affymetrix based technologies, we will determine which genes this activated form of STAT3 modifies in LPS stimulated macrophages. Furthermore, we will fully characterize the binding partners of STAT3 using proteomic techniques. We believe only by using both of these approaches will we finally gain insights, at the molecular level, as to how this important molecule functions.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>336993</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Reseach Seminar, Karolinska Institute Stockholm, Sweeden</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>BBA46082-EC14-424A-83E8-1FA0872FF34C</gtr:id><gtr:impact>40 people attended seminar and resulted in discussion afterwards

Found fellow reseacrhers with common interests and now collaborating with IL-10 group within Barts</gtr:impact><gtr:outcomeId>DNcDEBfVCtN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research seminar, William Harvey Research Institute (WHRI) at Barts</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D9DA54B4-CE5D-4F94-85E3-945FA1004A10</gtr:id><gtr:impact>30 people from the research department attended talk which lead to discussion afterwards

Found fellow reseacrhers with common interests</gtr:impact><gtr:outcomeId>snW7dY7CdKC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Streptactin (31 amnio acid C terminal tagged wild type STAT3)</gtr:description><gtr:id>B14664BC-8137-486C-862D-5797419A4A64</gtr:id><gtr:impact>none so far</gtr:impact><gtr:outcomeId>MVCtkvEENHE</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>purification tagged expression vector</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Human macrophages were either left unstimulated or stimulated with LPS, IL-10 or LPS+IL-10, or infected with a constitutively active STAT3 virus +/- LPS. RNA extracted after 1 hr and Affymetrix arrays perfomed.</gtr:description><gtr:id>8C9AD884-CF36-4571-8B22-9DE6356EFDB9</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>FB7213B2521</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Affymetrix expression profile of IL-10/ STAT3 induced genes</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>C terminal tagged 31 amino acid streptavdin binding protein STAT3 adenovirus which retains its biological activity.</gtr:description><gtr:id>B04CB9C3-CFB5-443B-9B08-7E6F61F24D65</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>a6jC8jDcueB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SBP tagged STAT3 adenovirus</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Streptactin (8 amnio acid N terminal tagged wild type STAT3)</gtr:description><gtr:id>9C2CF3D9-0C0E-4C8E-8A15-11B46F203616</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>LV25yDiZANC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>purification tagged expression vector</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>I have added protein G and the streptavidin-binding peptide tagged to N terminal wild STAT1, STAT3 and constitutively active STAT3 and geenerated adenoviral constructs.</gtr:description><gtr:id>20B2F219-3970-4284-890B-912B5DFEE58D</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>FA22AE9E3D2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GS  TAP tagged  STAT1, STAT3 and cSTAT3 adenoviral vectors</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>36D630A1-BA28-433B-95C4-9DD56B5638FC</gtr:id><gtr:title>Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0370a4b6b25eb32eedd6cf0f4fb9f807"><gtr:id>0370a4b6b25eb32eedd6cf0f4fb9f807</gtr:id><gtr:otherNames>Williams LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>845DE66BFC2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69BDCAD7-85A8-438F-A782-132CB0232494</gtr:id><gtr:title>Production of TNF-a in macrophages activated by T cells, compared with lipopolysaccharide, uses distinct IL-10-dependent regulatory mechanism.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9fcb700e60f007fe4f7ae54923c7da1"><gtr:id>e9fcb700e60f007fe4f7ae54923c7da1</gtr:id><gtr:otherNames>Agbanoma G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15818_28_22219323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7535C5E-662F-431B-B35D-1F185DE38238</gtr:id><gtr:title>Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d9286b1288f0125830189f9402670f2"><gtr:id>0d9286b1288f0125830189f9402670f2</gtr:id><gtr:otherNames>Sacre SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>9F31F001EB6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>375F801F-863C-4007-A8F6-6A53070B8E9E</gtr:id><gtr:title>Rac mediates TNF-induced cytokine production via modulation of NF-kappaB.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0370a4b6b25eb32eedd6cf0f4fb9f807"><gtr:id>0370a4b6b25eb32eedd6cf0f4fb9f807</gtr:id><gtr:otherNames>Williams LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>2D3BE16230A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10D50525-04EF-4CFB-A175-EA559B3DA7B5</gtr:id><gtr:title>Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor a-converting enzyme (TACE/ADAM-17) activation in primary human monocytes.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46438b487c710c2c88ca54789de2c239"><gtr:id>46438b487c710c2c88ca54789de2c239</gtr:id><gtr:otherNames>Scott AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>Q9bHb4gwWsR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18E892BB-A095-4745-B48F-ED4B468FA12F</gtr:id><gtr:title>Role of STAT3 in glucocorticoid-induced expression of the human IL-10 gene.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c456ad805eb89fd449e95346b93c3750"><gtr:id>c456ad805eb89fd449e95346b93c3750</gtr:id><gtr:otherNames>Unterberger C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>C81E0575081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACA4786A-6570-4D7E-9E10-56A89346C747</gtr:id><gtr:title>Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d032d83b9ba7ee1151ff9072dd40e07"><gtr:id>6d032d83b9ba7ee1151ff9072dd40e07</gtr:id><gtr:otherNames>Nicolaidou V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15818_28_22802946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCB5E397-6DF6-4E51-83D4-EFA586E29DF8</gtr:id><gtr:title>IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/745c202dafdb006637ca20a32d6798a5"><gtr:id>745c202dafdb006637ca20a32d6798a5</gtr:id><gtr:otherNames>Smallie T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>DtVkLqxt8Eb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA3B197B-B748-448F-A4E7-300739F76ACC</gtr:id><gtr:title>Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2aa5b89cb4297de4c1843a39caeec604"><gtr:id>2aa5b89cb4297de4c1843a39caeec604</gtr:id><gtr:otherNames>Lundberg AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>11BE1C92A93</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F108EC9E-EB45-4C4B-A4D4-358391F3F7CB</gtr:id><gtr:title>Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c86682d623f3aea9b6e79520fdad8a7a"><gtr:id>c86682d623f3aea9b6e79520fdad8a7a</gtr:id><gtr:otherNames>El Kasmi KC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>3FD87ACD3F5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6112B2C4-7911-4E9F-A187-C9B76BCECF0D</gtr:id><gtr:title>IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcription factor Stat3.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23e21b513fbcf9eaebb1499ccb74057a"><gtr:id>23e21b513fbcf9eaebb1499ccb74057a</gtr:id><gtr:otherNames>Staples KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>7D44D1C851C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>016DED03-2652-493D-8E7A-F674D5D813B3</gtr:id><gtr:title>Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89d3f62a74471b6f62340fa0f4903006"><gtr:id>89d3f62a74471b6f62340fa0f4903006</gtr:id><gtr:otherNames>Amat M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>D0182729FA9</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700128</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>